Faraday Pharmaceuticals is an early-stage therapeutics company focused on developing novel therapies to treat ischemia-reperfusion injury.
Faraday Pharmaceuticals has raised $52.8M in total funding. The most recent round was Series C. The last funding was announced in November 2022.
Faraday Pharmaceuticals's investors include ARCH Venture Partners, Polaris Partners, OUP (Osage University Partners), Alexandria Real Estate Equities, Washington Research Foundation.
Faraday Pharmaceuticals is headquartered in Seattle, United States.
Faraday Pharmaceuticals is an early-stage therapeutics company focused on developing novel therapies to treat ischemia-reperfusion injury.
Faraday Pharmaceuticals is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Faraday Pharmaceuticals — Funding & Investors." VCBacked, November 7, 2022, https://www.vcbacked.co/company/faraday-pharmaceuticals. Accessed September 30, 2026.
VCBacked. (2022). Faraday Pharmaceuticals — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/faraday-pharmaceuticals
{{cite web |title=Faraday Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/faraday-pharmaceuticals |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated